High computational requirements restrict the use of Monte Carlo algorithms for dose estimation in a clinical setting, despite the fact that they are considered more accurate than traditional methods. The goal of this study was to compare mean tumor absorbed dose estimates using the unit density sphere model incorporated in OLINDA with previously reported dose estimates from Monte Carlo simulations using the dose planning method (DPMMC) particle transport algorithm. The dataset (57 tumors, 19 lymphoma patients who underwent SPECT/CT imaging during I-131 radioimmunotherapy) included tumors of varying size, shape, and contrast. OLINDA calculations were first carried out using the baseline tumor volume and residence time from SPECT/CT imaging during 6 days post-tracer and 8 days post-therapy. Next, the OLINDA calculation was split over multiple time periods and summed to get the total dose, which accounted for the changes in tumor size. Results from the second calculation were compared with results determined by coupling SPECT/CT images with DPM Monte Carlo algorithms. Results from the OLINDA calculation accounting for changes in tumor size were almost always higher (median 22%, range -1%-68%) than the results from OLINDA using the baseline tumor volume because of tumor shrinkage. There was good agreement (median -5%, range -13%-2%) between the OLINDA results and the self-dose component from Monte Carlo calculations, indicating that tumor shape effects are a minor source of error when using the sphere model. However, because the sphere model ignores cross-irradiation, the OLINDA calculation significantly underestimated (median 14%, range 2%-31%) the total tumor absorbed dose compared with Monte Carlo. These results show that when the quantity of interest is the mean tumor absorbed dose, the unit density sphere model is a practical alternative to Monte Carlo for some applications. For applications requiring higher accuracy, computerintensive Monte Carlo calculation is needed.
Introduction
R adiolabeled antibody therapy, including I-131 radioimmunotherapy (RIT), has shown much success in the treatment of malignancies such as non-Hodgkin's lymphoma (NHL). 1, 2 The potential exists to further improve the efficacy of these therapies by individualized, dosimetry-based treatment planning. Thus, there is much interest in the accurate assessment of the radiation absorbed dose delivered to normal organs and tumor during therapy.
Conventionally, dosimetry in internal emitter therapy has been based on the S-value formalism developed by the Medical Internal Radiation Dose (MIRD) Committee. 3 Here, the absorbed dose to a target region from decays in a given source region is expressed as the product of the cumulated activity in the source region and the source-to-target S-value, which is the absorbed dose to the target region per unit cumulated activity in the source region. The total absorbed dose to a target is then calculated as the sum of contributions from self-irradiation (where target and source regions are the same) and from cross-irradiation (where target and source regions are different). The S-values for such calculations have been predetermined by Monte Carlo methods, originally for the ''Reference Man'' anatomy 4 and later for stylized models representing individuals of both sexes at several ages. 5 A major limitation of using reference S-values for absorbed dose estimation in patients is the potential for a significant difference between organ geometries of the individual patient and those of the models used to generate the S-values. In addition, the models of the human anatomy used to determine S-values do not include tumor, because tumors can be of arbitrary shape, size, and location within the anatomy.
For tumor dosimetry, the conventional approach has been based on a sphere model that assumes that tumors are isolated unit density spheres in an infinite unit density medium. This approach has been implemented in the OLINDA/EXM code, 6 which is often used for dosimetry calculations in internal emitter therapy. For any of the radionuclides included in the program, S-values for self-irradiation of unit density spheres are available for discrete sphere masses in the range 0.01-6000 g. These S-values have been precalculated based on the most recent evaluation of electron-and photonabsorbed fractions in spheres of various sizes. 7 Because organ-to-tumor cross-dose depends almost exclusively on the proximity of tumor relative to the organ and because tumor locations are arbitrary, organ-to-tumor S-values cannot be calculated for the general case. Therefore, dose estimates from this approach will account only for the self-dose and not for any cross-dose from any extratumor activity.
To overcome the obvious limitations of the simplistic sphere model, researchers have turned to other more patientspecific approaches to tumor dosimetry. [8] [9] [10] [11] [12] [13] One such approach is the dose point-kernel method, which is based on convolving the spatial distribution of activity with tabulated dose point-kernels for a specific isotope.
14 This method tends to be inaccurate when there are tissue inhomogeneities such as at tissue-air and tissue-bone interfaces.
14 Loudos et al. 15 have recently developed a patient-specific dosimetry method based on modifying tabulated dose point-kernels to account for the spatial variation in densities (derived from patient CTs) between source and target voxel centers. This method was not considered in this work as it was felt that the increased accuracy obtained by using a Monte Carlo-based dosimetry model outweighed the relatively modest computation time penalty incurred. The more sophisticated of the patient-specific tumor dosimetry methods couples 3D anatomical (from MRI or CT) and functional (from SPECT or PET) images of the patient with explicit Monte Carlo radiation-transport calculations. In a recent publication, highly patient-specific tumor dose assessment results for 60 tumors in 20 NHL patients who underwent I-131 tositumomab RIT were reported.
12 Dose assessment was carried out by coupling SPECT/CT imaging data at multiple time points with the Dose Planning Method Monte Carlo (DPMMC) radiation transport algorithm. 13 The voxel-level calculations were carried out, including deformable image registration to relate tumor voxels that are changing from one time point to another because of tumor regression or deformation. Registered tumor dose-rate maps were integrated over time to obtain the 3D dose distribution, which allowed for calculation of not only mean absorbed dose to the tumor but also other summary measures such as maximum dose and equivalent uniform dose. Such patientspecific dose assessment provides 3D dose distributions and is more accurate than a calculation based on reference Svalues. However, 3D imaging data are needed, in addition to high computational requirements. With recent advances in computer power and acceleration of Monte Carlo algorithms, these calculations can be carried out in a research environment, but such calculations are still not practical for the clinic. Therefore, when the quantity of interest is the mean absorbed dose to the target, comparison of results from patient-specific Monte Carlo calculations with results using reference S-values is clinically relevant to determine the level of accuracy that can be achieved with the simpler approach. Previous reports on such comparisons have either focused on organ dosimetry or were limited to simulated tumor geo metries. 16, 17 The goal of the present study is to compare mean tumor absorbed dose estimates using the unit sphere model incorporated in OLINDA with dose estimates from previously reported Monte Carlo calculations for NHL patients. Unlike previous reports, the present study uses actual patient SPECT/CT imaging data and tumors of varying size, shape, and uptake relative to background for this comparison.
Materials and Methods

Patient imaging data
The imaging data came from patients undergoing 131 Itositumomab therapy of relapsed or refractory B-cell lymphoma under an approved clinical protocol. The clinical treatment protocol 1 and the SPECT/CT imaging procedure under a research protocol 11, 12 have been previously described in detail and are summarized here. The administered diagnostic (tracer) activity was 185 MBq (5 mCi) and the therapy activity ranged from 2.15 to 5.68 GBq (58-153 mCi). For the research study, patients volunteered for imaging at multiple time points on the Siemens Symbia TruePoint SPECT/CT scanner. Patients were imaged three times following the tracer (days 0, 2, and 6) and three times following the therapy (days 2, 5, and 7-9). At each time point, a nuclear medicine specialist with radiology CT training defined the tumor volumes of interests on CT, plane by plane. Data for 60 tumors in 20 patients (13 men and 7 women; age range, 33-81 years) were available for the present calculations. One of these patients (patient 17 in Table 1 ), who developed human anti-mouse antibodies, had too few SPECT counts to perform dosimetry, so 19 patients with a total of 57 tumors were analyzed.
Tumor time-activity curves
The 3D SPECT reconstruction and activity quantification have been previously described 11, 12 and are summarized here. SPECT data were reconstructed with 35 iterations (6 subsets) of 3D ordered-subsets expectations maximization (OSEM) including triple-window-based scatter correction, CT-based attenuation correction, and compensation for 3D depth-dependent detector response. At each time point, the SPECT counts within the CT-defined tumor volume were converted to an activity using a calibration factor. Correction for partial volume effects was carried out by applying volumedependent recovery coefficients determined from phantom experiments. 12 Tumor time-activity data were generated for both tracer and therapy administrations. For the present study, the rest-of-the-body time-activity curves were not needed, as only the self-dose is determined in the OLINDA calculation. Time-activity data were fitted using a biexponential of the form A(t) ¼ c (e À kat À e ket ). 18 This function was analytically integrated over time to obtain the tumor residence time (cumulated activity divided by the administered activity) for the dosimetry calculations discussed later. The endpoint of the integration was somewhat arbitrarily chosen as 300 hours. The 300 hours time was selected, because the last imaging time point was typically about 150 hours postadministration for tracer and 190 hours postadministration for therapy and extrapolating too far from that time point could lead to greater variance in the results. The residence times when the timeactivity curve was integrated to infinity were within 5% of the values obtained by integrating to 300 hours for every tumor except one (patient 11, R psoas in Table 1 ). The activity clearance of this tumor was unusually slow, resulting in a residence time 53% higher when integrated to infinity. The 300 hours integration is consistent with the previous study in which Monte Carlo dose-rate maps were integrated up to this time to obtain the dose map. 12 Although much emphasis was placed on accurate SPECT activity quantification using state-of-the-art hybrid imaging and 3D OSEM reconstruction, inaccuracies can remain because of approximations made when correcting for physical factors, uncertainty in tumor volume determination, SPECT-CT misregistration, and the limited imaging time points. These inaccuracies will have a similar impact on the two absorbed dose calculation methods compared in the present work, because tumor time-activity data were generated in the same manner for both calculations.
Tumor dosimetry using the unit density sphere model For tumor dosimetry, the unit density sphere model implemented within OLINDA was used. Here, tumors are approximated as unit density spheres with uniformly distributed activity. The precalculated OLINDA sphere-model S-factors for I-131 were obtained for all available sphere sizes ranging from 0.01 to 6000 g. These S-values were plotted vs. sphere mass and the fitted function was used to determine the S-value for any mass. The dose equation based on the MIRD formalism can be expressed as follows:
Here, s is the residence time, Ã is the cumulated activity, A 0 is the patient's administered activity, and S is the dose per unit cumulated activity. The dosimetry calculation was carried out with and without accounting for changes in tumor size measured at the multiple imaging time points. In the first approach, the absorbed dose was estimated for a constant tumor mass corresponding to the outline defined on the day 0 post-tracer SPECT/CT (baseline mass). The tracer residence time was determined by integrating the tracer time-activity curve from 0 to 300 hours, and the therapy residence time was determined by integrating the therapy time-activity curve from 0 to 300 hours. To estimate the mean tumor absorbed dose from the tracer administration, the S-value corresponding to the baseline tumor mass and the tracer residence time were used in Equation 1. To estimate the mean tumor absorbed dose from the therapy administration, the S-value corresponding to the baseline tumor mass and the therapy residence time were used in Equation 1.
The availability of SPECT/CT imaging data and CTdefined tumor outlines at multiple time points favor splitting the OLINDA calculation over multiple time periods, which was done in the second approach. As imaging was carried out at three time points, three time periods were used for the calculation. A typical tumor time-activity curve with the three time periods (0 to t 1 , t 1 to t 2 , t 2 to 300 hours) is shown in Figure 1 . Here, T 1 , T 2 , and T 3 are the three imaging time points, t 1 is the midpoint between T 1 and T 2 , and t 2 is the midpoint between T 2 and T 3 . The total dose was calculated as the sum of the dose delivered over each of the three periods:
where s 1 , s 2 , and s 3 are the residence times for the three time periods determined by integrating the time-activity curve over each period, and S 1 , S 2 , and S 3 are the OLINDA Svalues corresponding to the tumor masses outlined at imaging time points T 1 , T 2 , and T 3 , respectively. This calculation was carried out separately for the tracer and the therapy imaging data. The dosimetry results from the OLINDA calculation carried out over multiple time periods according to Equation 2 were used for the comparison to the previous Monte Carlo results as this approach is more consistent with how the SPECT/CT data were previously utilized (SPECT/CT images and tumor outlines from each of the time points were input to the DPMMC algorithm to generate corresponding tumor dose-rate maps). 
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tumors are given in Table 1 , together with other relevant information useful for interpreting the dosimetry results. The tumor-to-background activity concentration ratio, B, is the activity per voxel in the tumor divided by the activity per voxel in the rest of the body (''rest of the body'' was defined as the total body section within the SPECT camera field of view minus the tumor). Also given in Table 1 are the baseline tumor volume defined on the first SPECT/CT and the decrease in tumor volume between this time point and the last SPECT/CT time point. The study included a wide range of tumor sizes (initial volume, 2-423 mL), tumor locations, and a wide range of B-values (2-19). Hence, there was a wide range in the level of cross-irradiation. The mean tumor absorbed dose results given in Table 1 are the total delivered from both the tracer and therapy administrations. Results from the OLINDA calculation using a baseline tumor mass and results from the OLINDA calculation carried out over the multiple time periods, accounting for changes in tumor mass, are given. Tumor absorbed doses calculated accounting for the mass changes were almost always higher than the absorbed doses calculated assuming a baseline tumor mass. The difference between the two OLINDA calculations ranged from -1% to 68%, with a median difference of 22%. The mean absorbed dose accounting for mass change was significantly higher than the mean absorbed dose without accounting for this change ( p < 0.001, paired t-test).
Next, the comparison between the mean tumor absorbed dose results from OLINDA and the previously reported Monte-Carlo-based, patient-specific calculation is presented in Table 1 . (Note that results from the OLINDA calculation over multiple time periods were used for this comparison.) OLIN-DA results were compared with both the self-dose and the total dose (sum of self-dose and cross-dose components) from the Monte Carlo calculation. Almost always, the OLINDA results were higher than the Monte Carlo self-dose, but only slightly. Although the mean absorbed self-dose from OLINDA was significantly higher than the mean absorbed self-dose from Monte Carlo ( p < 0.001, paired t-test), the difference between these two calculations was small, ranging from -13% to 2%, with a median difference of only -5%. The OLINDA results were always lower than the Monte Carlo total dose, and the difference between the two ranged from 2% to 31%, with a median difference of 14%. The mean absorbed dose from OLINDA was significantly lower than the mean absorbed total dose from Monte Carlo ( p < 0.001, paired t-test).
Discussion
For most of the 57 tumors, significant tumor shrinkage was measured during the SPECT/CT imaging. Because of the inverse relationship between absorbed dose and mass, the OLINDA calculation carried out over multiple time periods gave significantly higher (up to 68%) absorbed doses than the calculation assuming baseline tumor masses. Conventionally, tumor dosimetry in internal emitter therapy has been carried out assuming a constant tumor mass, typically obtained from a diagnostic CT study performed before the treatment. The present results demonstrate the inadequacy of such an approach for dosimetry of malignant lymphoma, which can have dramatic shrinkage within days of the treatment. 12, 19 When tumor volume information from multiple time points is available, a reasonable approach is to carry out the OLINDA calculation over multiple time periods as in the present study.
The unit density sphere model implemented within OLINDA assumes all tumors are spherical, whereas the DPM Monte Carlo calculation utilizes the actual tumor contour outlined on CT. In all cases, the DPMMC self-dose was lower than the OLINDA calculation, because in reality tumors are nonspherical (see e.g., Fig. 2 ) and more beta particles can escape from a nonspherical geometry without depositing all of their energy compared with a spherical geometry of the same volume. However, the relatively good agreement between the OLINDA results and the DPMMC self-dose results (see Table 1 ) shows that the sphere approximation is reasonable and shape effects are not a major source of error. This is due to the I-131 beta emission, which has a mean energy of 192 keV and has a short range (2.3 mm 20 in water) compared to the size of the tumors of the present dataset (smallest radius around 8 mm, 16 times larger than the range of the beta particle). Shape effects may lead to more errors in calculations for Y-90 RIT, which has a higher energy beta emission (mean energy of 938 keV), leading to a greater range in water (11.3 mm 20 ). In Table 1 , the comparison between OLINDA results and the total DPMMC absorbed doses showed significant differences (up to 31%). As expected, the total DPMMC dose was higher, because the sphere model ignores the contribution from Table 1 . 
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activity outside the sphere. In general, the difference between results of DPMMC and OLINDA increases as the tumor-tobackground activity concentration ratio (B-value in Table 1 ) decreases because of the increasing contribution from crossirradiation. There are, however, exceptions, because the contribution to tumor dose from cross-irradiation depends not only on the B-value but also on the size of the tumor and the proximity of the tumor to structures with significant uptake. As calculated, the B-value assumes a uniform activity distribution in the rest of the body, but in reality there is enhanced I-131 uptake in the liver, kidneys, spleen, and heart. In addition, the contribution from cross-irradiation is very much dependent on the photon energy, and hence, the trends observed in the present I-131 study may not be applicable to therapies with other radionuclides. In a previous study, the photon contribution to tumor dose from I-131 activity outside the tumor was calculated by Monte Carlo for simulated tumors positioned in the Reference Man geometry. 16 The underestimation of tumor dose due to neglecting this contribution was found to be in the range 10%-20%, which is comparable to the results of the present study. In a more recent study, focusing mainly on normal organ dosimetry Divoli et al. 17 reported on the differences between results obtained using patient-specific Monte Carlo methodology and results obtained using the reference S-values implemented in OLINDA. Individual patient's CT images (total of 9 patients) were used to define the normal organs, whereas published biodistribution data were used to assign cumulated activities. When a mass correction (available in OLINDA) was used to account for differences in organ masses between the patient and the standard model, good agreement (within 5%) was demonstrated. For normal organs, agreement between the two calculations can be expected to be better than the agreement for tumor, because the cross-irradiation contribution is included in the OLINDA calculation for normal organs. The work by Divoli et al. also included tumor, but was limited to two small (7 g each) spherical tumors, artificially placed in the liver and the lung. The good agreement ( < 5%) between Monte Carlo and OLINDA in that reported for tumor was attributed to the limited nature of the study. Tumors of different size, shape, and varying levels of uptake relative to background were not investigated as in the present work.
Conclusions
For NHL patients treated with I-131 tositumomab RIT, the mean tumor absorbed doses determined using the unit density sphere model in OLINDA were compared with previously reported results from explicit Monte Carlo simulation using the DPMMC algorithm. SPECT/CT imaging data from multiple time points were used in both calculations. The dataset included tumors of varying sizes and shapes as well as varying uptake relative to the rest of the body. There was good agreement when the OLINDA results were compared with the self-dose component from the Monte Carlo calculation, indicating that assuming a spherical shape for the tumor was not a major source of error. However, because the sphere model ignores cross-irradiation, this calculation significantly underestimated (median 14%, range 2%-31%) the total absorbed dose compared with Monte Carlo. Although the tumor dosimetry calculation using the sphere model is much more practical than the computerintensive Monte Carlo method, its level of accuracy may not be acceptable for some treatment planning applications. Tumor-to-rest-of-the-body activity concentration ratio. 
